Cargando…
Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439413/ https://www.ncbi.nlm.nih.gov/pubmed/28420699 http://dx.doi.org/10.2337/dc17-er06b |
| _version_ | 1783237945509019648 |
|---|---|
| author | Mita, Tomoya Katakami, Naoto Yoshii, Hidenori Onuma, Tomio Kaneto, Hideaki Osonoi, Takeshi Shiraiwa, Toshihiko Kosugi, Keisuke Umayahara, Yutaka Yamamoto, Tsunehiko Yokoyama, Hiroki Kuribayashi, Nobuichi Jinnouchi, Hideaki Gosho, Masahiko Shimomura, Iichiro Watada, Hirotaka |
| author_facet | Mita, Tomoya Katakami, Naoto Yoshii, Hidenori Onuma, Tomio Kaneto, Hideaki Osonoi, Takeshi Shiraiwa, Toshihiko Kosugi, Keisuke Umayahara, Yutaka Yamamoto, Tsunehiko Yokoyama, Hiroki Kuribayashi, Nobuichi Jinnouchi, Hideaki Gosho, Masahiko Shimomura, Iichiro Watada, Hirotaka |
| author_sort | Mita, Tomoya |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5439413 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-54394132018-06-01 Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148 Mita, Tomoya Katakami, Naoto Yoshii, Hidenori Onuma, Tomio Kaneto, Hideaki Osonoi, Takeshi Shiraiwa, Toshihiko Kosugi, Keisuke Umayahara, Yutaka Yamamoto, Tsunehiko Yokoyama, Hiroki Kuribayashi, Nobuichi Jinnouchi, Hideaki Gosho, Masahiko Shimomura, Iichiro Watada, Hirotaka Diabetes Care Errata American Diabetes Association 2017-06 2017-04-18 /pmc/articles/PMC5439413/ /pubmed/28420699 http://dx.doi.org/10.2337/dc17-er06b Text en © 2017 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
| spellingShingle | Errata Mita, Tomoya Katakami, Naoto Yoshii, Hidenori Onuma, Tomio Kaneto, Hideaki Osonoi, Takeshi Shiraiwa, Toshihiko Kosugi, Keisuke Umayahara, Yutaka Yamamoto, Tsunehiko Yokoyama, Hiroki Kuribayashi, Nobuichi Jinnouchi, Hideaki Gosho, Masahiko Shimomura, Iichiro Watada, Hirotaka Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148 |
| title | Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148 |
| title_full | Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148 |
| title_fullStr | Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148 |
| title_full_unstemmed | Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148 |
| title_short | Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148 |
| title_sort | erratum. alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (spead-a). diabetes care 2016;39:139–148 |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439413/ https://www.ncbi.nlm.nih.gov/pubmed/28420699 http://dx.doi.org/10.2337/dc17-er06b |
| work_keys_str_mv | AT mitatomoya erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT katakaminaoto erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT yoshiihidenori erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT onumatomio erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT kanetohideaki erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT osonoitakeshi erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT shiraiwatoshihiko erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT kosugikeisuke erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT umayaharayutaka erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT yamamototsunehiko erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT yokoyamahiroki erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT kuribayashinobuichi erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT jinnouchihideaki erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT goshomasahiko erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT shimomuraiichiro erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 AT watadahirotaka erratumalogliptinadipeptidylpeptidase4inhibitorpreventstheprogressionofcarotidatherosclerosisinpatientswithtype2diabetesthestudyofpreventiveeffectsofalogliptinondiabeticatherosclerosisspeadadiabetescare201639139148 |